Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Gastric Cancer. 2018 Aug 7;22(2):355–362. doi: 10.1007/s10120-018-0861-7

Figure 3.

Figure 3.

Genomic analysis of advanced HER2-positive gastric cancer. Oncoprint depicts alterations in selected genes of interest in 11 HER2-positive gastric cancer patients treated with mDCF and trastuzumab. Correlation with progression-free survival (a) and overall survival (b) are described.